Dr. Koo on Next-Generation Imaging in Prostate Cancer

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center in Arizona, discusses next-generation imaging tools in prostate cancer.

18F-fluciclovine (Axumin) is the next-generation imaging tool that is widely available and best performing, explains Koo. The performance of 18F-fluciclovine thus far has been as good or better than choline C-11, which was the first novel radiopharmaceutical PET agent that was approved in the United States, says Koo.

Conventional imaging tools have focused on bone and CT scan, but many lesions were missing on these scans, according to Koo. This is important because when looking at salvage therapies or potential curative interventions, physicians should be aware if the disease is metastatic and where it might be confined, concludes Koo.